FibroGen Reports Q1 2024 Financial Results

May 7, 2024

DENVER, Colo., May 07, 2024 (247marketnews.com)- FibroGen, Inc. (NASDAQ:FGEN) reported its first quarter 2024 financial results and provided an update on the company’s recent developments.

Total first quarter revenue for 2024 was $55.9 million, a 55% year over year increase, from $36.2 million, for the first quarter of 2023, driven by net product revenue in China and one-time drug product revenue of $25.7 million recognized due to the termination of US/RoW AstraZeneca agreement.

Net loss for the first quarter improved from $76.7 million, or $0.81 net loss per basic and diluted share, in 2023 to $32.9 million, or $0.33 net loss per basic and diluted share, for 2024.

“We are off to a strong start in 2024 marked by the recent release of compelling Phase 1 data on FG-3246, our CD46 targeted antibody drug conjugate, in metastatic castration-resistant prostate cancer and continued robust growth of our roxadustat business in China,” commented FibroGen’s CEO, Thane Wettig. “Looking ahead, we expect to report topline data from our two late-stage clinical trials of pamrevlumab in pancreatic cancer in the coming months. In addition, we have a strong balance sheet and reaffirm our cash runway into 2026.”

FibroGen reported $214.7 million in cash and equivalents that provides a runway into 2026.

About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community. Visit 24/7 Market News website here.

24/7 MARKET NEWS, INC Disclaimer
Please go to https://247marketnews.com/disclaimer/ for disclaimer information.

CONTACT:
24/7 Market News
Editor@247marketnews.com

Related news for (FGEN)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.